NCT01335711 - CHRONVAC-C Study Followed by Standard of Care in Chronic Hepatitis C Virus (HCV) Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2011

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions

Chronic Hepatitis C

Interventions

DRUG

ChronVac-C + SOC

"IMP: I.m. administration of 500 μg plasmid DNA vaccine CHRONVAC-C (solution for injection) administered i.m. in combination with electroporation using MedPulser® DDS on 2 occasions with 4 weeks in between followed by standard of care (SOC) initiation after 14 - 42 days.~SOC: Peg-IFN-α-2a (180 μg per week) and Ribavirin (1000 mg/day for subjects with a BW of \< 75 kg and 1200 mg/day for subjects with a BW of \> 75 kg)"

DRUG

SOC

SOC: Peg-IFN-α-2a (180 μg per week) and Ribavirin (1000 mg/day for subjects with a BW of \< 75 kg and 1200 mg/day for subjects with a BW of \> 75 kg)

Trial Locations (2)

SE-141 86

RECRUITING

I73 Department of Infectious Diseases, Karolinska Institute, Karolinska University Hospital, Huddinge

SE-581 85

RECRUITING

Division of Infectious Diseases, Department of Clinical and experimental medicine, Faculty of Health Sciences, Linköping University, Department of Infectious Diseases, County Council of Östergötland, Linköping